MPH Share Price Performance
CA$1.29
0.41 (46.59%)
Price CA$1.29
Share Pricen/a
Medicure Inc. (CVE:MPH) Surges 29% Yet Its Low P/S Is No Reason For Excitement
Nov 11
Medicure Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
MPH Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Medicure Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 19, 2025
- -0.13
- 55.14%
- -5.83%
- 0%
About MPH
- Founded
- 1997
- Employees
- n/a
- CEO
- WebsiteView website
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.
